AstraZeneca : A better Q3 than anticipated, a change to the Dato registration process, no new comments on China
>Q3 better than expected, Symbicort again delivers a positive surprise - AstraZeneca has just published results for Q3 2024 which proved better than expected. Revenue was up +21% at constant currency (cc) driven by the oncology (+22%), CVRM (+20%) and respiratory (+29%) franchise. We see no major difference vis-a-vis forecasts for the group’s core products but we would note an excellent performance over the quarter from Symbicort, as well as Tezspire which came in res...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.